"Pfizer Meds for iPhone": A Useful Mobile App, Except for One Problem...
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - January 17, 2014 Category: Pharma Commentators Tags: Adherence Apps Mobile mobile medical app Pfizer Source Type: blogs
The New MedAdNews Will Focus on Old School "Narcissistic Advertising"
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - January 16, 2014 Category: Pharma Commentators Tags: Manny Awards MedAdNews Trade publications Source Type: blogs
FDA Says It Has & Will Release Bits and Pieces of Long-Awaited Social Media Guidance Before July 2014 Deadline
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - January 14, 2014 Category: Pharma Commentators Tags: #fdasm Guidance social media Source Type: blogs
Analysis of FDA's Draft Guidance Relating to Postmarketing Submission of Interactive Promotional Media
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - January 13, 2014 Category: Pharma Commentators Tags: #fdasm Guidance Internet social media Source Type: blogs
What Makes a "Memorable" DTC Ad? The Restasis Case Study
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - January 10, 2014 Category: Pharma Commentators Tags: Allergan DTC Advertising Restasis Source Type: blogs
Is FDA Seeking NSA Capabilities?
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - January 8, 2014 Category: Pharma Commentators Tags: FDA Guidance social media Source Type: blogs
PBAfacts.com: No Laughing Matter
A couple of nights ago while watching TV, a strange ad appeared and caught my attention before I could fast forward. The ad showed "People who Burst out crying" and who "lAugh uncontrollably." At first my wife and I thought it was a Robert Smigel, SNL comedy spoof. My wife asked "Is this for real?" Then we realized, yes, it was for real. It was a PseudoBulbar Affect awareness ad by Avanir Pharmaceuticals, which markets NUEDEXTA, a treatment for this condition.The ad promoted a free PBA "Facts Kit," which includes patient stories and one of those "self assessment" quizzes. I...
Source: Pharma Marketing Blog - December 31, 2013 Category: Pharma Commentators Tags: DTC Advertising Symptom Quiz Source Type: blogs
Pharmaguy's Predictions for 2014
Last year at this time I made "Some Interesting Pharma Predictions for 2013". How well did I do? Well, although there is still one day left in 2013, let's review a couple of last year's predictions and then see what's in my crystal ball for 2014.What I predicted for 2013: "Direct-to-Consumer (DTC) Spending Will Continue to Decline" I based this on the general economy, which I thought would still be in bad shape and thus continue to have a "negative impact on DTC advertising causing a slow death by a thousand cuts."Early data for the first half of 2013 as reported by Pharmalot, howe...
Source: Pharma Marketing Blog - December 30, 2013 Category: Pharma Commentators Tags: DTC Advertising FDA Guidance social media Source Type: blogs
Where Have All the (Critical) Pharma Bloggers Gone, Long Time Passing?
Effective December 31, 2013, UBM Canon will cease producing the MedAdNews, Pharmalive, Pharmalot, eKnowledgeBase and R&D Directions brands (read the announcement here). Everyone in the Pharma Blogosphere was surprised and saddened by this announcement. I think Richard Meyer of World of DTC Marketing Blog expressed it best:"This is a loss for the industry that is very much at a crossroads of marketing to patient, consumers and health care professionals. Ed Silverman, the author of Pharmalot, will especially be missed as his voice and stories added insight to the complex and changing world of healthcare marketing....
Source: Pharma Marketing Blog - December 24, 2013 Category: Pharma Commentators Tags: Pharma Blogosphere Pharmalot Source Type: blogs
Can Pharma Marketing and R&D Profitably Coexist?
John LaMattina over at Forbes blog (here) is very concerned about the drug industry's current reputation, which has sunk to new lows since George W. Merck made this comment:"We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear. The better we have remembered it, the larger they have been.""The culprits in this decline have been corporate types," says LaMattina, "particularly the sales and marketing folks (my emphasis), who are perceived as relentlessly driving to maximize profits at...
Source: Pharma Marketing Blog - December 20, 2013 Category: Pharma Commentators Tags: R & D Reputation Research Source Type: blogs
Pharma: The Year 2013 in Images
These are my favorite images that appeared in Pharma Marketing Blog posts made in 2013. It was a very interesting year, at least for me. Unfortunately, to date, it has been another year without FDA social media guidance! See slide #12 for this year's anti-Abrams image. Enjoy! Pharma Marketing Blog: The Year 2013 in Images from Pharma Guy (Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - December 19, 2013 Category: Pharma Commentators Tags: 2013 images Source Type: blogs
Beware of Tweets Made by Hired Guns: Do You Have a Policy for That?
An ex-employee of Gedeon Richter, which is the largest biotechnology and pharmaceutical company based in Hungary, complained to the Prescription Medicines Code of Practice Authority (PMCPA) -- the policing arm of the Association of the British Pharmaceutical Industry (ABPI) -- about two tweets sent by an events company engaged by Gedeon Richter.The first tweet, which was sent on 9 November 2012, read "Register for the event 'Sharing surgical experience after the use of ulipristal acetate in fibroid patients'". The second tweet, sent on 22 November 2012, read "Places available at the Nottingham sympos...
Source: Pharma Marketing Blog - December 17, 2013 Category: Pharma Commentators Tags: ABPI PMCPA Regulation Twitter Source Type: blogs
Should UnBranded Disease Awareness Ads Mention Treatment Risks?
False and misleading drug ads can harm con-sumers and the healthcare system. In order to limit the harm from false Rx drug advertising, FDA’s Office of Prescription Drug Promotion (OPDP) tracks several kinds of regulatory violations such as:Risk omission or minimization Superiority claims Overstatement of efficacy Unsubstantiated claim Broadening of indication Promotion of an unapproved use Promotion of an unapproved compoundAccording EyeforPharma, which has compiled data from FDA Warning and Notice of Violation Letters since 2004, "omission" or "minimization" of risk information is by far the m...
Source: Pharma Marketing Blog - December 16, 2013 Category: Pharma Commentators Tags: #Pharma100 ADHD Celebrity Endorsement Disease awareness Regulation Shire Source Type: blogs
Being Too "Patient-Centric": Spying on Patients on Social Media
I've written recently about the need for pharmaceutical companies to institute Customer Experience Centers of Excellence (here). This was in response to hearing about several other types of "Centers of Excellence" popping up inside pharma companies and my conversation with Dyan Bryson, VP, Patient Enablement Services at Indegene Lifesystems Pvt. Ltd., about "putting the patient at the center" (listen to podcast "Why is Putting the Patient at the Center So Difficult?")."Patient-Centricity" seems to be an overused buzzword among pharma marketers these days. So overused that Michael...
Source: Pharma Marketing Blog - December 11, 2013 Category: Pharma Commentators Tags: patient-centricity social media Source Type: blogs
Does Pharma Really Need a 12-Step Program for Recovery of It's Reputation? Or Will One Step Be Sufficient?
You've heard of the 12-Step Program of Alcohol Anonymous and you may have even heard of "The Twelve Steps of Pharma Social Marketers Anonymous" (here). But have you heard of the "12 [Steps the] Pharma Industry Can [Take] to Rebuild Real Public Trust" posted by Luke Timmerman over at Xconomy blog (here)?I usually don't like lists for a number of reasons (see "10 Reasons Why I Hate Lists"), but I like 12-Step lists because I can paraphrase the AA steps so that they are relevant to the pharmaceutical industry as I did here.But rather than do that, let me review a few of the steps recommen...
Source: Pharma Marketing Blog - December 9, 2013 Category: Pharma Commentators Tags: Drug prices Reputation Source Type: blogs
